Other languages COMPASS Pathways plc

Equities

CMPS

US20451W1018

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
6.91 ^USD	-7.50%		-7.25%	-21.03%

Jun. 05	Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating	MT
Jun. 04	FDA panel to review psychedelic drug MDMA for first time	RE

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA panel to review psychedelic drug MDMA for first time	Jun. 04
COMPASS Pathways plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder	May. 08
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression	Apr. 29
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	Apr. 18
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	Apr. 18
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	Apr. 02
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	Apr. 02
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	Apr. 01
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	Apr. 01
Compass Pathways Co-Founders Step Down From Board; David Norton Named Interim Chair; Shares Fall	Mar. 28
COMPASS Pathways plc Announces Board Changes	Mar. 28
Compass Pathways Insider Sold Shares Worth $704,821, According to a Recent SEC Filing	Mar. 15
Compass Pathways Insider Sold Shares Worth $704,821, According to a Recent SEC Filing	Mar. 15
COMPASS Pathways plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
COMPASS Pathways plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Compass Pathways Insider Sold Shares Worth $609,862, According to a Recent SEC Filing	Feb. 27
Compass Pathways Insider Sold Shares Worth $609,862, According to a Recent SEC Filing	Feb. 27
Compass Pathways Insider Sold Shares Worth $902,124, According to a Recent SEC Filing	Feb. 08
Compass Pathways Insider Sold Shares Worth $902,124, According to a Recent SEC Filing	Feb. 08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages COMPASS Pathways plc

Equities

CMPS

US20451W1018

Other languages

Filters